Product Images Tadalafil

The text describes a graph showing the mean changes in IPSS (International Prostate Symptom Score) in patients with BPH (benign prostatic hyperplasia) treated with tadalafil tablets of 5 mg dosage or placebos. The changes are displayed based on the treatment duration of up to 12 weeks.*

This appears to be a graph or chart displaying the change from baseline in IPSS (International Prostate Symptom Score) total score in BPH (Benign Prostatic Hyperplasia) patients treated with Tadalafil Tablet 5 mg over a duration of 12 weeks. The X-axis represents the duration of treatment in weeks, and the Y-axis represents the mean IPSS changes at each visit. However, without the actual graph or chart, it is difficult to provide a more detailed description.*

The text describes a graph showing the mean total IPSS changes by visit in BPH patients taking Tadalafil Tablet with Finasteride. The x-axis in the graph represents the number of weeks of therapy, while the y-axis represents the least-squares treatment difference and the LS mean change from baseline. There are two groups being compared, Tadalafil/Finasteride and Placebo/Finasteride. The text also indicates that there is statistical significance (p<0.05) in the LS mean change from baseline for the Tadalafil/Finasteride group compared to the Placebo/Finasteride group.*

The text describes a chart showing the change in IPSS total score in ED/BPH patients using Tadalafil Tablet 5mg and placebo over a period of 12 weeks. The chart shows that there is a significant difference in IPSS total score between the two groups (p<0.01). The text indicates that the chart is from "Study L".*

This appears to be a table or graph displaying the results of a study comparing different doses and timings of tadalafil and doxazosin on blood pressure. The table shows the dosages and timings administered, as well as the resulting blood pressure measurements.*

This is a graph that shows the concentration of Tadalafil in plasma in micrograms per liter (ug/L) at different time intervals (in hours) after the administration of different doses. The graph compares the concentrations achieved by a single 20-mg Tadalafil dose, a single 5-mg Tadalafil dose, and a once-daily 5-mg Tadalafil dose after five consecutive days of administration.*

Product description: This text consists of information about a medication named "oo smarwens Tafalafil Tablets, USP" with the National Drug Code (NDC) 62332-178-30. The format of the information appears to be a label or packaging of the medication. There is also a code on the label, GTIN: 0362332178308, and information related to the manufacturer, "Pramac il Lintad". There is no further useful information in this text.*

Not available. The text appears to be a combination of random letters, numbers, and symbols that do not form a coherent description or piece of information.*

This is a description for Tadalafil Tablets, USP manufactured by Wbl Praramsasials. The tablets come in a bottle with NDC 62332-180-30 and should be stored at room temperature. The recommended dosage and other usage instructions are illegible. The product is available for prescription only.*